¼¼°èÀÇ °æÄ«Å×ÅÍ ½ÉÀåÆÇ¸· ½ÃÀå
Transcatheter Heart Valves
»óǰÄÚµå : 1768769
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 247 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °æÄ«Å×ÅÍ ½ÉÀåÆÇ¸· ½ÃÀåÀº 2030³â±îÁö 436¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 173¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ °æÄ«Å×ÅÍ ½ÉÀåÆÇ¸· ½ÃÀåÀº 2030³â¿¡´Â 436¾ï ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 16.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ(TAV)Àº CAGR 16.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 314¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °æÄ«Å×ÅÍ ½Â¸ðÆÇ(TMV) ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 15.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 44¾ï ´Þ·¯, Áß±¹Àº CAGR 21.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °æÄ«Å×ÅÍ ½ÉÀåÆÇ¸· ½ÃÀåÀº 2024³â¿¡ 44¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 111¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 21.2%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 11.6%¿Í 14.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 12.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ °æÄ«Å×ÅÍ ½ÉÀåÆÇ¸· ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°æÇÇÀû Ä«Å×ÅÍ ½ÉÀå ÆÇ¸·ÀÌ ½ÉÀ庴ÇÐÀÇ ÆÇµµ¸¦ ¹Ù²Ü ¼ö ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

°æÄ«Å×ÅÍ ½ÉÀå ÆÇ¸· ġȯ¼úÀº ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõ°ú °°Àº ½É°¢ÇÑ ½ÉÀå ÆÇ¸· ÁúȯÀ» ¾Î°í Àִ ȯÀڵ鿡°Ô ±âÁ¸ÀÇ °³½É¼úÀ» ´ëüÇÒ ¼ö ÀÖ´Â ÃÖ¼Ò Ä§½ÀÀû ¼ö¼úÀ» Á¦°øÇÔÀ¸·Î½á ½ÉÀåÇÐ ºÐ¾ßÀÇ È¹±âÀûÀÎ Áøº¸¸¦ »ó¡ÇÕ´Ï´Ù. Å« ÈäºÎ Àý°³¿Í Àΰø ½ÉÆó Àåºñ°¡ ÇÊ¿äÇÑ ±âÁ¸ÀÇ ¿Ü°úÀû ÆÇ¸· ġȯ¼ú°ú ´Þ¸®, °æÄ«Å×ÅÍ ½ÉÀå ÆÇ¸· ġȯ¼úÀº ÀϹÝÀûÀ¸·Î »ì¼­Á¦³ª °¡½¿ÀÇ ÀÛÀº Àý°³Ã¢À» ÅëÇØ Ä«Å×Å͸¦ ÅëÇØ Á¢ÀÌ½Ä ÆÇ¸·À» »ðÀÔÇÕ´Ï´Ù. ÀÏ´Ü ÆÇ¸·ÀÌ ¼³Ä¡µÇ¸é ÆÇ¸·ÀÌ È®ÀåµÇ¾î Áï½Ã ÀÛµ¿Çϱ⠽ÃÀÛÇÏ¿© °³½É¼ú ¾øÀ̵µ Á¤»óÀûÀÎ Ç÷·ù¸¦ ȸº¹ÇÕ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ±âÁ¸ ¼ö¼ú¿¡ ¼ö¹ÝµÇ´Â ½ÅüÀû ¿Ü»ó°ú ȸº¹ ½Ã°£À» Å©°Ô ÁÙ¿© °í·ÉÀÇ È¯ÀÚ³ª ¼ö¼ú À§ÇèÀÌ ³ô°í ±âÁ¸ ¼ö¼úÀÌ ÀûÇÕÇÏÁö ¾ÊÀº ȯÀڵ鿡°Ô ÀûÇÕÇÑ ¼±ÅÃÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ÁÖ¿ä ±â¼úÀº °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR)·Î, ¼ö¼ú¿¡ ºñÇØ ³·Àº ÇÕº´Áõ ¹ß»ý·ü·Î ÀÎÇØ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, TAVRÀÇ ¼º°øÀº ½Â¸ðÆÇ¸·°ú »ï÷ÆÇ¸·À» Æ÷ÇÔÇÑ ´Ù¸¥ ½ÉÀå ÆÇ¸·¿¡ ´ëÇÑ °æÄ«Å×ÅÍ ¼Ö·ç¼ÇÀÇ °³¹ß¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. °æÄ«Å×ÅÍ ÆÇ¸· ÁßÀç½Ã¼úÀÇ Ä¡·á ¹üÀ§¸¦ È®´ëÇß½À´Ï´Ù. ÀÔ¿ø ±â°£ ´ÜÃà, ¼ö¼ú ÈÄ ÅëÁõ °¨¼Ò, ȸº¹ ½Ã°£ ´ÜÃà µî °æÇÇÀû Ä«Å×ÅÍ ½ÉÀå ÆÇ¸·Àº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ½ÉÇ÷°ü Ä¡·áÀÇ Ç¥ÁØ Ä¡·á¹ýÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù.

°æÄ«Å×ÅÍ ½ÉÀå ÆÇ¸·ÀÇ Çõ½ÅÀº ½ÉÀå Ä¡·áÀÇ ¹Ì·¡¸¦ ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

°æÇÇÀû Ä«Å×ÅÍ ½ÉÀåÆÇ¸· ºÐ¾ß´Â Àç·á °úÇÐ, ±â±â ¼³°è ¹× ½Ã¼ú¹ýÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ±Þ¼ÓÇÑ ±â¼ú Çõ½ÅÀ» ¸ñ°ÝÇϰí ÀÖÀ¸¸ç, ±× °á°ú ÀÌ·¯ÇÑ ±¸¸í ÀåºñÀÇ ¾ÈÀü¼º, À¯È¿¼º ¹× ´Ù¿ëµµ¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ Çõ½Å Áß Çϳª´Â ³»±¸¼ºÀÌ Çâ»óµÇ°í º¹ÀâÇÑ ÇØºÎÇÐÀû ±¸Á¶¿¡ ÀûÀÀÇÒ ¼ö ÀÖ´Â Â÷¼¼´ë °æÇÇÀû Ä«Å×ÅÍ ¹ëºêÀÇ °³¹ßÀÔ´Ï´Ù. ÀÌ »õ·Î¿î Àåºñ¿¡´Â ´ÏƼ³î(Çü»ó±â¾ïÇÕ±Ý)°ú °°Àº ÷´Ü ¼ÒÀç°¡ Æ÷ÇԵǾî ÀÖÀ¸¸ç, ¹ëºê°¡ ÀÚüÀûÀ¸·Î ÆØÃ¢Çϰí ȯÀÚÀÇ ÇØºÎÇÐÀû ±¸Á¶¿¡ ´õ Àß ÀûÀÀÇÒ ¼ö ÀÖÀ¸¸ç, ´õ ³ªÀº ÀûÇÕ¼ºÀ» º¸ÀåÇÏ°í ´©Ãâ ¹× ÇÕº´ÁõÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ Çõ½ÅÀº Á¶Á÷ °øÇÐ ¹× »ýüÈí¼ö¼º ¹ëºê ±¸¼º ¿ä¼Ò¸¦ »ç¿ëÇÏ¿© ¹ëºê ÀåºñÀÇ Àå±âÀûÀÎ ¼º´ÉÀ» Çâ»ó½ÃŰ°í ¼®È¸È­ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ »õ·Î¿î Àü´Þ ½Ã½ºÅÛ°ú ´õ ÀÛÀº Ä«Å×ÅÍ Å©±â´Â ´õ ÀÛÀº Ç÷°üÀ» ÅëÇØ Á¢±ÙÀÌ °¡´ÉÇÏ¿© Ç÷°ü ÇÕº´ÁõÀÇ À§ÇèÀ» ´õ¿í ÁÙÀ̰í, ´õ ÀûÀº ¿Ü»óÀ¸·Î ½Ã¼úÀ» ÇÒ ¼ö ÀÖ°Ô ÇØÁÖ¸ç, 3D ½ÉÃÊÀ½ÆÄ ¹× CT À¯µµÇÏ ³»ºñ°ÔÀ̼ǰú °°Àº ¿µ»ó ±â¼úµµ Çõ½ÅÀûÀÔ´Ï´Ù. ÀÇ Çõ½ÅÀº ½Ã¼úÀÇ Á¤È®¼ºÀ» ³ôÀ̰í, ÆÇ¸·ÀÇ Á¤È®ÇÑ À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ°Ô ÇÏ¿© ÇÕº´Áõ À§ÇèÀ» °¨¼Ò½Ã۰í ÀÖ½À´Ï´Ù. µðÁöÅÐ Çコ ±â¼úÀÇ ÅëÇÕµµ Å« È帧À¸·Î, ÀϺΠ±â±â¿¡´Â ¼¾¼­¿Í ¹«¼± ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÌ ³»ÀåµÇ¾î ÀÖÀ¸¸ç, ÆÇ¸·ÀÇ ¼º´É°ú ȯÀÚÀÇ °Ç°­ »óÅ¿¡ ´ëÇÑ ½Ç½Ã°£ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© »çÀü °ü¸® ¹× Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

°æÇÇÀû Ä«Å×ÅÍ ½ÉÀåÆÇ¸·ÀÇ Ã¤Åðú °³¹ß¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °úÁ¦´Â?

°æÄ«Å×ÅÍ ½ÉÀå ÆÇ¸·ÀÇ º¸±Þ°ú °³¹ßÀº Çõ½ÅÀûÀÎ ÀáÀç·Â¿¡µµ ºÒ±¸ÇÏ°í ¸î °¡Áö ½É°¢ÇÑ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÁÖ¿ä °úÁ¦ Áß Çϳª´Â ÀÌ·¯ÇÑ ½Ã¼ú°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀÔ´Ï´Ù. °æÇÇÀû Ä«Å×ÅÍ ÆÇ¸· ġȯ¼ú, ƯÈ÷ TAVRÀº °í°¡ÀÇ Àåºñ, Àü¹® ±³À°, °í±Þ ¿µ»ó Áø´Ü ¹× ½Ã¼ú¿ë Àåºñ¸¦ ÇÊ¿ä·Î ÇÏ´Â ÀÚ¿ø Áý¾àÀûÀÎ °úÁ¤À̱⠶§¹®¿¡ ƯÈ÷ Àú¼ÒµæÃþÀ̳ª ³óÃÌ È¯°æ¿¡¼­´Â Á¢±Ù¼ºÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ °úÁ¦´Â ȯÀÚ ¼±Åðú ½Ã¼ú °èȹÀÇ º¹À⼺ÀÔ´Ï´Ù. Á÷Á¢ ´«À¸·Î º¸¸é¼­ ½ÃÇàÇÏ´Â ±âÁ¸ÀÇ ¼ö¼úÀû ÆÇ¸· ġȯ¼ú°ú ´Þ¸®, °æÄ«Å×ÅÍ ½Ã¼úÀº ÆÇ¸·ÀÇ ¹èÄ¡¸¦ ¾È³»Çϱâ À§ÇØ ½ÉÃÊÀ½ÆÄ, CT ½ºÄµ, Åõ½Ã µîÀÇ ¿µ»ó Áø´Ü¿¡ Å©°Ô ÀÇÁ¸ÇÕ´Ï´Ù. ÀÌ ¶§¹®¿¡ ÷´Ü Àü¹® Áö½Ä°ú Á¤È®ÇÑ ÇØºÎÇÐÀû Æò°¡°¡ ÇÊ¿äÇϸç, »õ·Î¿î ½Ã¼úÀÚ¿¡°Ô´Â ÇнÀ °î¼±ÀÌ °¡ÆÄ¸£°í °æÇèÀÌ ºÎÁ·ÇÑ ¼¾ÅÍ¿¡¼­´Â ÀÌ·¯ÇÑ ½Ã¼úÀÇ ÅëÇÕÀÌ º¹ÀâÇØÁý´Ï´Ù. ¶ÇÇÑ °æÄ«Å×ÅÍ ½ÉÀå ÆÇ¸·ÀÇ Àå±âÀûÀÎ ³»±¸¼ºÀº ƯÈ÷ ÀþÀº ȯÀÚÀÇ °æ¿ì, ÀåºñÀÇ ¼ö¸íº¸´Ù ´õ ±æ¾îÁú ¼ö ÀÖ´Â Àå±âÀûÀÎ ³»±¸¼º¿¡ ´ëÇÑ ¿ì·Á°¡ ¿©ÀüÈ÷ Á¸ÀçÇÕ´Ï´Ù. »õ·Î¿î Àç·á¿Í µðÀÚÀÎÀº ³»±¸¼ºÀ» ¿¬ÀåÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖÁö¸¸, 10-15³â ÀÌ»óÀÇ Àå±â °á°ú¿¡ ´ëÇÑ µ¥ÀÌÅÍ´Â ¿©ÀüÈ÷ Á¦ÇÑÀûÀ̾ ÀÌ·¯ÇÑ ½Ã¼ú¿¡ °¡Àå ÀûÇÕÇÑ È¯ÀÚ ÇÁ·ÎÆÄÀÏÀ» °áÁ¤ÇϱⰡ ¾î·Æ½À´Ï´Ù. Ä«Å×ÅÍ »ðÀԽà ÆÇ¸·´©Ãâ, ÆÇ¸· Ç÷ÀüÁõ, Ç÷°ü ¼Õ»ó°ú °°Àº ÇÕº´Áõ À§Çèµµ ȯÀÚ ¿¹ÈÄ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ¹®Á¦ÀÔ´Ï´Ù. ±ÔÁ¦ »óȲ°ú »óȯ ¹®Á¦µµ »óȲÀ» º¹ÀâÇÏ°Ô ¸¸µé°í ÀÖÀ¸¸ç, °æÇÇÀû Ä«Å×ÅÍ ÀåºñÀÇ ½ÂÀÎ ±âÁذú »óȯ ±âÁØÀº Áö¿ª¸¶´Ù Å©°Ô ´Ù¸¥ °æ¿ì°¡ ¸¹½À´Ï´Ù.

°æÄ«Å×ÅÍ ½ÉÀåÆÇ¸· ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

°æÄ«Å×ÅÍ ½ÉÀåÆÇ¸· ½ÃÀåÀÇ ¼ºÀåÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, ¼¼°è Àα¸ÀÇ °í·ÉÈ­, Àåºñ ¼³°è ¹× ½Ã¼úÀÇ ±â¼ú ¹ßÀü µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõ ¹× ±âŸ ½ÉÀå ÆÇ¸· ÁúȯÀÇ À¯º´·ü Áõ°¡, ƯÈ÷ ³ëÀÎÀÇ °æ¿ì ¼ö¼ú À§ÇèÀÌ ³ô±â ¶§¹®¿¡ Àúħ½ÀÀû °æÇÇÀû Ä«Å×ÅÍ ½Ã¼úÀÌ È¿°úÀûÀÏ °¡´É¼ºÀÌ ³ô´Ù´Â Á¡ÀÔ´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿¡ µû¶ó ȸº¹ÀÌ ºü¸£°í ÇÕº´ÁõÀÌ ÀûÀº ÃÖ¼Ò Ä§½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, °æÇÇÀû ½ÉÀå ÆÇ¸·Àº Á¡Á¡ ´õ ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿øµ¿·ÂÀº ÀÌ·¯ÇÑ ÀåºñÀÇ ÀÓ»ó ÀûÀÀÁõ È®´ëÀÔ´Ï´Ù. Ãʱ⿡´Â °íÀ§Ç豺 ¼ö¼ú Èĺ¸ÀÚ¸¦ ´ë»óÀ¸·Î ½ÂÀÎµÈ °æÇÇÀû Ä«Å×ÅÍ ÆÇ¸· ġȯ¼úÀº ÀÓ»ó½ÃÇèÀ» ÅëÇØ ¼ö¼úÀû ÆÇ¸· ġȯ¼ú°ú µ¿µîÇϰųª ±× ÀÌ»óÀÇ Ä¡·á È¿°ú¸¦ ÀÔÁõÇÏ¿© ÇöÀç ÀúÀ§Ç豺 ȯÀڵ鿡°Ôµµ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀûÀÀÁõ È®´ë·Î Ä¡·á ´ë»ó ȯÀÚ±ºÀÌ Å©°Ô È®´ëµÇ¾î ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀçÀ§Ä¡ ¹× ȸ¼ö °¡´ÉÇÑ ÆÇ¸·, ´õ ÀÛÀº Å©±âÀÇ Àü´Þ ½Ã½ºÅÛ, ÷´Ü ¿µ»ó Áø´Ü Åø¿Í °°Àº ±â¼ú Çõ½ÅÀ¸·Î ÀÎÇØ ½Ã¼úÀÌ ´õ¿í ¾ÈÀüÇϰí È¿°úÀûÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ½ÉÀå Àü¹®ÀÇ, ¿Ü°úÀÇ»ç, ¿µ»óÀÇÇаú Àü¹®Àǰ¡ Çù·ÂÇÏ¿© ÃÖ¼±ÀÇ Ä¡·á °èȹÀ» °áÁ¤ÇÏ´Â ½ÉÀå ÆÀ Á¢±Ù¹ýÀÇ Ã¤ÅÃÀÌ È®´ëµÇ¸é¼­ ȯÀÚ ¼±Åðú ½Ã¼ú °á°ú°¡ °³¼±µÇ°í, °æÇÇÀû Ä«Å×ÅÍ »ðÀÔ¼úÀÇ Àü¹ÝÀûÀÎ ¼º°ø·üÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Àü¹® ±³À° ¹× ±³À° ±¸»ó¿¡ ÈûÀÔ¾î Àü ¼¼°è º´¿ø¿¡¼­ °æÇÇÀû Ä«Å×ÅÍ ÆÇ¸· Àü¿ë ÇÁ·Î±×·¥ÀÌ »ý°Ü³ª¸é¼­ ÇÊ¿äÇÑ ÀÎÇÁ¶ó¿Í Àü¹® Áö½ÄÀ» ±¸ÃàÇÏ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î °æÇÇÀû Ä«Å×ÅÍ ½ÉÀå ÆÇ¸·ÀÇ ÀåÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÀϺΠÁö¿ªÀÇ À¯¸®ÇÑ »óȯ Á¤Ã¥°ú ÇÔ²² ÀÌ·¯ÇÑ ½Ã¼úÀÌ ´õ¿í Ä£¼÷ÇØÁ® ´õ ³ôÀº äÅ÷üÀ» À̲ø¾î³»°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀ» Á¾ÇÕÇØ º¼ ¶§, °æÇÇÀû ½ÉÀåÆÇ¸· ½ÃÀåÀº °ß°íÇÑ ¼ºÀå ±Ëµµ¸¦ ±×¸®¸ç ÁßÀçÀû ½ÉÀåÇп¡¼­ Áß¿äÇÑ ±¸¼º ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(°æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ(TAV), °æÄ«Å×ÅÍ ½Â¸ðÆÇ(TMV)), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, Ä«Å×ÅÍ °Ë»ç½Ç)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Transcatheter Heart Valves Market to Reach US$43.6 Billion by 2030

The global market for Transcatheter Heart Valves estimated at US$17.3 Billion in the year 2024, is expected to reach US$43.6 Billion by 2030, growing at a CAGR of 16.6% over the analysis period 2024-2030. Transcatheter Aortic Valve (TAV), one of the segments analyzed in the report, is expected to record a 16.9% CAGR and reach US$31.4 Billion by the end of the analysis period. Growth in the Transcatheter Mitral Valve (TMV) segment is estimated at 15.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 21.2% CAGR

The Transcatheter Heart Valves market in the U.S. is estimated at US$4.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.1 Billion by the year 2030 trailing a CAGR of 21.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.6% and 14.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.8% CAGR.

Global Transcatheter Heart Valves Market - Key Trends and Drivers Summarized

What Makes Transcatheter Heart Valves a Game-Changing Advancement in Cardiology?

Transcatheter heart valves represent a groundbreaking advancement in the field of cardiology, offering a minimally invasive alternative to traditional open-heart surgery for patients suffering from severe heart valve diseases such as aortic stenosis. Unlike conventional surgical valve replacement procedures that require a large chest incision and a heart-lung machine, transcatheter heart valve procedures involve the insertion of a collapsible valve via a catheter, typically through a small incision in the groin or chest. Once in place, the valve expands and starts functioning immediately, restoring normal blood flow without the need for open-heart surgery. This approach significantly reduces the physical trauma and recovery time associated with traditional surgery, making it a viable option for elderly patients or those with high surgical risk who may not be candidates for conventional procedures. The primary technology in this field is Transcatheter Aortic Valve Replacement (TAVR), which has gained widespread adoption due to its proven efficacy and lower complication rates compared to surgical options. The success of TAVR has spurred the development of transcatheter solutions for other heart valves, including the mitral and tricuspid valves, expanding the therapeutic scope of transcatheter valve interventions. With shorter hospital stays, reduced postoperative pain, and faster recovery times, transcatheter heart valves are not only improving patient outcomes but are also transforming the standard of care in cardiovascular treatment.

How Are Innovations in Transcatheter Heart Valves Shaping the Future of Cardiac Care?

The field of transcatheter heart valves is witnessing rapid innovation, driven by advancements in material science, device design, and procedural techniques, which are enhancing the safety, efficacy, and versatility of these life-saving devices. One of the most significant innovations is the development of next-generation transcatheter valves that offer enhanced durability and adaptability to complex anatomies. These new devices incorporate advanced materials such as nitinol-a shape-memory alloy that allows the valves to be self-expanding and more conformable to the patient’s anatomy, ensuring a better fit and reducing the risk of leaks or complications. Another key innovation is the use of tissue-engineered and bioresorbable valve components, which aim to improve the long-term performance of the devices and minimize the risk of calcification. Furthermore, new delivery systems and smaller catheter sizes are making it possible to perform these procedures with even less trauma, allowing access through smaller vessels and further reducing the risk of vascular complications. Innovations in imaging technology, such as 3D echocardiography and CT-guided navigation, are also enhancing procedural precision, enabling more accurate placement of the valve and reducing the risk of complications. The integration of digital health technologies is another major trend, with some devices incorporating sensors and wireless monitoring systems that provide real-time data on valve performance and patient health, allowing for proactive management and timely interventions.

What Challenges Are Affecting the Adoption and Development of Transcatheter Heart Valves?

Despite their transformative potential, the adoption and development of transcatheter heart valves face several significant challenges that need to be addressed to optimize their use and expand their reach. One of the primary challenges is the high cost associated with these procedures. Transcatheter valve replacement, particularly TAVR, is a resource-intensive process that involves expensive devices, specialized training, and sophisticated imaging and procedural equipment, which can limit accessibility, especially in low-income and rural settings. Another challenge is the complexity of patient selection and procedural planning. Unlike traditional surgical valve replacement, which is performed under direct visualization, transcatheter procedures rely heavily on imaging modalities such as echocardiography, CT scans, and fluoroscopy to guide valve placement. This demands a high level of expertise and precise anatomical assessment, making the learning curve steep for new operators and complicating the integration of these procedures into less experienced centers. Additionally, the long-term durability of transcatheter heart valves remains a concern, especially for younger patients who may outlive the lifespan of the device. Although newer materials and designs are aimed at extending durability, data on long-term outcomes beyond 10-15 years is still limited, making it difficult to determine the optimal patient profile for these procedures. The risk of complications, such as paravalvular leak, valve thrombosis, or vascular damage during catheter insertion, also poses challenges that can impact patient outcomes. Regulatory hurdles and reimbursement issues also complicate the landscape, as the approval and reimbursement criteria for transcatheter devices are often vary significantly between regions.

What Factors Are Driving Growth in the Transcatheter Heart Valve Market?

The growth in the transcatheter heart valve market is driven by several factors, including the rising prevalence of cardiovascular diseases, an aging global population, and technological advancements in device design and procedural techniques. One of the primary drivers is the increasing incidence of aortic stenosis and other valvular heart diseases, particularly among the elderly, who are often at higher surgical risk and thus more likely to benefit from minimally invasive transcatheter options. As the global population ages, the demand for less invasive treatments that offer faster recovery and fewer complications is rising, making transcatheter heart valves an increasingly preferred choice. Another key driver is the expansion of clinical indications for these devices. Originally approved for high-risk surgical candidates, transcatheter valve replacement procedures are now being performed in lower-risk patients, following clinical trials that demonstrated comparable or superior outcomes to surgical valve replacement. This broadening of indications is significantly expanding the patient pool eligible for these treatments, driving market growth. Technological advancements are also propelling the market, with innovations such as repositionable and retrievable valves, smaller delivery systems, and advanced imaging tools that are making the procedures safer and more effective. Furthermore, the growing adoption of heart team approaches-where cardiologists, surgeons, and imaging specialists collaborate to determine the best treatment plan-has improved patient selection and procedural outcomes, enhancing the overall success rate of transcatheter interventions. The rise of dedicated transcatheter valve programs in hospitals around the world, supported by specialized training and educational initiatives, is also contributing to market growth by building the necessary infrastructure and expertise. Lastly, increasing awareness of the benefits of transcatheter heart valves, coupled with favorable reimbursement policies in several regions, is making these procedures more accessible and driving higher adoption rates. These factors collectively indicate a robust growth trajectory for the transcatheter heart valve market, positioning it as a key component of interventional cardiology.

SCOPE OF STUDY:

The report analyzes the Transcatheter Heart Valves market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Transcatheter Aortic Valve (TAV), Transcatheter Mitral Valve (TMV)); End-Use (Hospital, Cath lab)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 16 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â